W. Umstead John - Jan 3, 2024 Form 4 Insider Report for G1 Therapeutics, Inc. (GTHX)

Signature
/s / Monica Roberts Thomas, attorney-in-fact
Stock symbol
GTHX
Transactions as of
Jan 3, 2024
Transactions value $
-$2,298
Form type
4
Date filed
1/8/2024, 06:04 AM
Previous filing
May 12, 2023
Next filing
Mar 20, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GTHX Common Stock Award $0 +37.3K +39.73% $0.00 131K Jan 3, 2024 Direct F1, F2, F3
transaction GTHX Common Stock Sale -$789 -253 -0.19% $3.12 131K Jan 3, 2024 Direct F4, F5, F6
transaction GTHX Common Stock Sale -$1.18K -379 -0.29% $3.12 131K Jan 3, 2024 Direct F4, F5, F7
transaction GTHX Common Stock Sale -$327 -111 -0.09% $2.94 130K Jan 4, 2024 Direct F4, F8, F9

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GTHX Stock Options (Right to Buy) Award $0 +74.5K $0.00 74.5K Jan 3, 2024 Common Stock 74.5K $2.97 Direct F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a restricted stock unit ("RSU") award that vests 25% on January 3, 2025 and 12.5% semi-annually thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
F10 The shares underlying this option vest as to 25% of the shares on January 3, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
F2 Each RSU represents a contingent right to receive one share of Issuer common stock.
F3 Represents (i) 2,749 shares of common stock; (ii) 637 RSUs from award granted on January 4, 2021; (iii) 2,500 RSUs from award granted on January 3, 2022; (iv) 3,000 RSUs from award granted on January 3, 2023; (v) 50,000 RSUs from award granted on March 15, 2023; (vi) 35,000 RSUs from award granted on May 10, 2023; and (vii) 37,300 RSUs from award granted on January 3, 2024.
F4 The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the Reporting Person.
F5 The price represents the weighted average price with a low of $3.08 and a high of $3.16. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 Represents (i) 2,996 shares of common stock; (ii) 637 RSUs from award granted on January 4, 2021; (iii) 2,000 RSUs from award granted on January 3, 2022; (iv) 3,000 RSUs from award granted on January 3, 2023; (v) 50,000 RSUs from award granted on March 15, 2023; (vi) 35,000 RSUs from award granted on May 10, 2023; and (vii) 37,300 RSUs from award granted on January 3, 2024.
F7 Represents (i) 3,367 shares of common stock; (ii) 637 RSUs from award granted on January 4, 2021; (iii) 2,000 RSUs from award granted on January 3, 2022; (iv) 2,250 RSUs from award granted on January 3, 2023; (v) 50,000 RSUs from award granted on March 15, 2023; (vi) 35,000 RSUs from award granted on May 10, 2023; and (vii) 37,300 RSUs from award granted on January 3, 2024.
F8 The price represents the weighted average price with a low of $2.89 and a high of $3.00. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F9 Represents (i) 3,468 shares of common stock; (ii) 425 RSUs from award granted on January 4, 2021; (iii) 2,000 RSUs from award granted on January 3, 2022; (iv) 2,250 RSUs from award granted on January 3, 2023; (v) 50,000 RSUs from award granted on March 15, 2023; (vi) 35,000 RSUs from award granted on May 10, 2023; and (vii) 37,300 RSUs from award granted on January 3, 2024.